Ex Parte Akashe et al - Page 5



          Appeal No. 2005-2629                                                        
          Application No. 10/377,474                                                  

               In the present case, while appellants make the argument that           
          the emulsions of Cope contain components that are not recited in            
          the appealed claims, appellants have advanced no compelling                 
          rationale, let alone objective evidence, which demonstrates that            
          the soy protein of Cope would be rendered ineffective as an anti-           
          oxidant by the components of the reference composition.  As                 
          pointed out by the examiner, appealed claim 1 does not quantify             
          the amount of reduction in the rate of oxidation.  Moreover, the            
          claims on appeal, by virtue of using "comprising," do not                   
          preclude the presence of additional components which are not                
          recited.  Since the USPTO does not have the facilities and                  
          wherewithal to test the properties of prior art compositions, it            
          is fair to place upon appellants the burden of establishing that            
          the emulsions of Cope do not exhibit a reduction in the rate of             
          oxidation of the lipids due to the presence of the soy protein.             
          Appellants maintain that the formulation of Cope is not identical           
          with the composition of the appealed claims.  However, it is not            
          necessary that the compositions be identical in order to fairly             
          place upon appellants the burden of demonstrating that the soy              
          protein of Cope does not reduce the rate of oxidation of the                
          omega-3 polyunsaturated lipid.                                              


                                         -5-                                          



Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007